A Robust Platform for the Molecular Design of Potent, Protease-Stable, Long-Acting GIP Analogues
- 8 March 2024
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 67 (6) , 4998-5010
Abstract
Glucose-dependent insulinotropic peptide (GIP) is a 42-amino acid peptide hormone that regulates postprandial glucose levels. GIP binds to its cognate receptor, GIPR, and mediates metabolic physiology by improved insulin sensitivity, β-cell proliferation, increased energy consumption, and stimulated glucagon secretion. Dipeptidyl peptidase-4 (DPP4) catalyzes the rapid inactivation of GIP within 6 min in vivo. Here, we report a molecular platform for the design of GIP analogues that are refractory to DPP4 action and exhibit differential activation of the receptor, thus offering potentially hundreds of GIP-based compounds to fine-tune pharmacology. The lead compound from our studies, which harbored a combination of N-terminal alkylation and side-chain lipidation, was equipotent and retained full efficacy at GIPR as the native peptide, while being completely refractory toward DPP4, and was resistant to trypsin. The GIP analogue identified from these studies was further evaluated in vivo and is one of the longest-acting GIPR agonists to date.Keywords
Funding Information
- Tufts Medical Center
- Division of Diabetes, Endocrinology, and Metabolic Diseases (DK131842)
- National Institute on Aging (AG061909)
- Tufts University
- National Institute of General Medical Sciences (GM130257, GM142448)
This publication has 74 references indexed in Scilit:
- The expanding incretin universe: from basic biology to clinical translationDiabetologia, 2023
- The Sustained Effects of a Dual GIP/GLP-1 Receptor Agonist, NNC0090-2746, in Patients with Type 2 DiabetesCell Metabolism, 2017
- D-Ala2-GIP-glu-PAL is neuroprotective in a chronic Parkinson's disease mouse model and increases BNDF expression while reducing neuroinflammation and lipid peroxidationEuropean Journal of Pharmacology, 2017
- Oligomerization of a Glucagon-like Peptide 1 Analog: Bridging Experiment and SimulationsBiophysical Journal, 2015
- Mechanisms underlying the rapid degradation and elimination of the incretin hormones GLP-1 and GIPBest Practice & Research Clinical Endocrinology & Metabolism, 2009
- Albumin as a drug carrier: Design of prodrugs, drug conjugates and nanoparticlesJournal of Controlled Release, 2008
- Four weeks of near-normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with type 2 diabetesDiabetologia, 2008
- The biology of incretin hormonesCell Metabolism, 2006
- Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patientsDiabetologia, 2002
- Improved stability, insulin-releasing activity and antidiabetic potential of two novel N-terminal analogues of gastric inhibitory polypeptide: N-acetyl-GIP and pGlu-GIPDiabetologia, 2002